NCT07360665 Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With Long-Acting Injectable Antipsychotics
| NCT ID | NCT07360665 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Trás-os-Montes and Alto Douro |
| Condition | Psychotic Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2026-01-01 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People with psychotic disorders, such as schizophrenia, often experience significant difficulties in daily functioning, physical health, and quality of life. Long-acting injectable antipsychotics are an important part of treatment, but they can be associated with metabolic side effects and reduced physical fitness. Physical exercise has shown potential benefits for mental and physical health in this population; however, structured exercise programs implemented in real-world psychiatric services are still limited. The purpose of this study is to evaluate the feasibility and clinical impact of a structured, multimodal physical exercise program for adults with psychosis who are receiving long-acting injectable antipsychotic treatment. The study aims to determine whether participation in a supervised exercise program can improve physical functioning, psychological well-being, and selected biological markers related to brain health and metabolism. This study will be conducted in an outpatient psychiatric setting in Portugal and will include adults diagnosed with psychosis who are currently treated with long-acting injectable antipsychotics. Participants will be allocated to either an exercise group or a control group receiving usual care. The exercise program will last 24 weeks and will include aerobic, strength, mobility, and flexibility exercises, with supervised sessions conducted by qualified professionals. Participants will be assessed at baseline, during the intervention, after completion of the program, and at follow-up. Assessments will include measures of physical function, body composition, psychological well-being, quality of life, and blood-based biomarkers such as brain-derived neurotrophic factor, dopamine, serotonin, and metabolic indicators. The main hypothesis of this study is that individuals who participate in the physical exercise program will show improvements in physical function, mood, and overall well-being compared with those receiving usual care alone. The results of this study are expected to provide practical evidence to support the integration of structured physical exercise as an adjunct to routine psychiatric care for people with psychosis.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older; * Clinical diagnosis of psychosis; * Currently undergoing treatment with long-acting injectable antipsychotics (LAIs); * Follow-up at the Antipsychotic Clinic of ULSTMAD; * Certificate of autonomy issued by the treating psychiatrist, confirming the participant's capacity to engage in the study procedures; * Ability to provide written informed consent, either personally or through a legal representative; * (Experimental group only) Residence within a reasonable distance from the physical exercise intervention site to allow attendance at supervised sessions. Exclusion Criteria: * Attendance below 85% of the supervised exercise sessions (experimental group); * Failure to complete the four main assessment time points; * Withdrawal or lack of informed consent at any stage of the study; * Not prescribed long-acting injectable antipsychotics (LAIs); * Not affiliated with or followed at the Antipsychotic Clinic of ULSTMAD.
Frequently Asked Questions
Who can join the NCT07360665 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psychotic Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07360665 currently recruiting?
Yes, NCT07360665 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Trás-os-Montes and Alto Douro to inquire about joining.
Where is the NCT07360665 trial being conducted?
This trial is being conducted at Vila Real, Portugal.
Who is sponsoring the NCT07360665 clinical trial?
NCT07360665 is sponsored by University of Trás-os-Montes and Alto Douro. The trial plans to enroll 44 participants.